CiPA update: in vitro cardiac ion channel screens, in silico models and stem cell iPS cardiomyocyte assays for proarrhythmia risk prediction

Presentation by Marc Rogers (Metrion CSO) at the June 2016 Sophion Ion Channel Modulation Symposium, Clare College, Cambridge (UK). CiPA update: in vitro cardiac ion channel screens, in silico models and stem cell iPS cardiomyocyte assays for proarrhythmia risk prediction.

Recommended Publications

Latest Publications

Early In Vitro Preclinical Cardiovascular Safety Assessment for Smarter Drug Discovery

Aligos Therapeutics and Metrion explore key approaches to cardiovascular safety screening in drug discovery.

Webinar recording - Accelerating Pain Therapeutic Discovery: Nav1.9 as a Drug Target for Treatment of Pain

Academic case study on Nav1.9 as a drug target by Associate Professor David Bulmer (University of Cambridge). Overview of Metrion’s newly developed Nav1.9 screening assays by Metrion CSO, Dr. Eddy Stevens.

View All

Application of a High-Throughput Human Stem Cell Cardiomyocyte Assay for Predicting Drug-Induced Changes in ECG Parameters During Drug Discovery and Development

Metrion shortlisted for 'Sales Team of the Year' and 'Campaign of the Year' at the Life Science Sales and Marketing Awards 2025

View All